Comparative Pharmacology
Head-to-head clinical analysis: DIURIL versus METHYCLOTHIAZIDE AND DESERPIDINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIURIL versus METHYCLOTHIAZIDE AND DESERPIDINE.
DIURIL vs METHYCLOTHIAZIDE AND DESERPIDINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits sodium reabsorption in the distal convoluted tubule by blocking the sodium-chloride symporter, leading to increased excretion of sodium, chloride, and water.
Methyclothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume; deserpidine is a Rauwolfia alkaloid that depletes catecholamines from peripheral sympathetic nerve endings, lowering peripheral vascular resistance.
Adults: 500 mg to 1000 mg orally once or twice daily; maximum 2000 mg per day.
One tablet (5 mg methyclothiazide / 0.25 mg deserpidine) orally once daily. Maximum dose: one tablet daily.
None Documented
None Documented
Terminal elimination half-life is 6-15 hours (mean 10 hours). In renal impairment, half-life can exceed 24 hours.
Methyclothiazide: terminal half-life 17-24 hours, permitting once-daily dosing. Deserpidine: 50-100 hours, allowing accumulation with repeated dosing.
Primarily renal (90-95% excreted unchanged via glomerular filtration and tubular secretion); minimal biliary/fecal (<5%).
Methyclothiazide: primarily renal excretion (60-70% unchanged) via tubular secretion; Deserpidine: extensive hepatic metabolism, <1% excreted unchanged in urine, with metabolites excreted in urine (40%) and feces (60%).
Category C
Category C
Thiazide Diuretic
Thiazide Diuretic and Antihypertensive